Timothy P. Noyes - 03 Jan 2023 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol: JBIO
Transactions as of: 03 Jan 2023
Net transactions value: -$373,976
Form type: 4
Filing time: 05 Jan 2023, 16:00:21 UTC
Previous filing: 02 Dec 2022
Next filing: 03 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AVTE	Common Stock	Options Exercise	$32,100	+15,000		$2.14^*	15,000	03 Jan 2023	Direct	F1
transaction	AVTE	Common Stock	Sale	$319,611	-11,927	-80%	$26.80	3,073	03 Jan 2023	Direct	F1, F2
transaction	AVTE	Common Stock	Sale	$63,256	-2,267	-74%	$27.90	806	03 Jan 2023	Direct	F1, F3
transaction	AVTE	Common Stock	Sale	$22,762	-791	-98%	$28.78	15	03 Jan 2023	Direct	F1, F4
transaction	AVTE	Common Stock	Sale	$447	-15	-100%	$29.82	0	03 Jan 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVTE	Stock Option (Right to Buy)	Options Exercise	$0	-15,000	-3.1%	$0.000000	463,381	03 Jan 2023	Common Stock	15,000	$2.14	Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.26 to $27.17, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.32 to $28.29, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.56 to $29.40, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5	A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.